[1] Wang AY, Yu AW, Li PK, et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis:analysis of a 9-year experience of fungal peritonitis in a single center[J]. Am J Kidney Dis, 2000, 36(4):1183-1192. [2] Bargman JM, Hospital TG. Characteristics and outcomes of fungal peritonitis in a modern North American cohort[J]. Perit Dial Int, 2015, 35(1):78-84. [3] Miles R, Hawley CM, McDonald SP, et al. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients[J].Kidney Int, 2009, 76(6):622-628. [4] Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations:2010 update[J].Perit Dial Int, 2010, 30(4):393-423 [5] Matuszkiewicz-Rowinska J. Update on fungal peritonitis and its treatment[J]. Perit Dial Int, 2009, 29:161-165. [6] Oygar DD, Altiparmak MR, Murtezaoglu A, et al. Fungal peritonitis in peritoneal dialysis:risk factors and prognosis[J]. Ren Fail, 2009, 31(1):25-28. [7] Goldie SJ, Kiernan-Tridle L, Torres C, et al. Fungal peritonitis in a large chronic peritoneal dialysis population:a report of 55 episodes[J]. Am J Kidney Dis,1996, 28(1):86-91. [8] Shouci Hu, Ren Tong, Yang Bo, et al. Fungal peritonitis in peritoneal dialysis:5-year review from a North China center[J].Infection, 2019, 47(1):35-43. [9] 赵洪静,许坤,吴永贵.腹膜透析相关性真菌性腹膜炎易感因素及预后分析[J]. 安徽医学,2015, 1(36):26-29. [10] Szeto CC, Li PK. Peritoneal dialysis-associated peritonitis[J].Clin J Am Soc Nephrol, 2019,14(7):1100-1105. [11] Hu S, Ming P, Qureshi AR, et al. Peritonitis:episode sequence, microbiological variation, risk factors and clinical outcomes in a North China peritoneal dialysis center[J]. Kidney Blood Press Res, 2018, 43(5):1573-1584. [12] Zalunardo NY, Rose CL, Ma IW, et al. Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis[J].Kidney Int, 2007, 71(7):687-692. [13] Pfaller MA, Castanheira M, Messer SA, et al. In vitro anti-fungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents:data from the SENTRY antifungal surveillance program, 2010 through 2012[J]. Mycoses, 2015, 58(4):209-214. [14] Kumar KV, Mallikarjuna HM, Gokulnath. Fungal peritonitis in continuous ambulatory peritoneal dialysis:the impact of antifungal prophylaxis on patient and technique outcomes[J]. Indian J Nephrol, 2014, 24(5), 297-301. [15] Rajendran R, Williams C, Lappin DF et al. Extracellular DNA release acts as an antifungal resistance mechanism in matureAspergillus fumigatus biofilms[J]. Eukaryot Cell, 2013,12(3):420-429. [16] Auricchio S, Giovenzana ME, Pozzi M et al. Fungal peritonitis in peritoneal dialysis:a 34-year single centre evaluation[J]. Clin Kidney J, 2018, 11(6); 874-880. [17] Munshi R, Sethna CB, Richardson, et al. Fungal peritonitis in the standardizing care to improve outcomes in pediatric end stage renal disease (SCOPE) collaborative[J]. Pediatric Nephrology, 2018, 33(5):873-880. [18] Wong PN, Lo KY, Tong GM, et al. Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD[J]. Perit Dial Int, 2007, 27(5):531-536. |